Patents by Inventor Ulrich-Peter Rohr

Ulrich-Peter Rohr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-INVASIVE TEST TO PREDICT RESPONSE TO THERAPY IN COLORECTAL CANCER PATIENTS
    Publication number: 20230083203
    Abstract: The invention is a method of predicting response to therapy in a colorectal cancer patient, the method comprising analysis of circulating tumor DNA from a patient's sample.
    Type: Application
    Filed: October 14, 2022
    Publication date: March 16, 2023
    Inventors: John Lee, Alexander Lovejoy, John Palma, Ulrich-Peter Rohr, Lijing Yao, Stephanie Yaung
  • Non-invasive test to predict response to therapy in colorectal cancer patients
    Patent number: 11519037
    Abstract: The invention is a method of predicting response to therapy in a colorectal cancer patient, the method comprising analysis of circulating tumor DNA from a patient's sample.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: December 6, 2022
    Assignee: ROCHE SEQUENCING SOLUTIONS, INC.
    Inventors: John Lee, Alexander Lovejoy, John Palma, Ulrich-Peter Rohr, Lijing Yao, Stephanie Yaung
  • NON-INVASIVE TEST TO PREDICT RESPONSE TO THERAPY IN COLORECTAL CANCER PATIENTS
    Publication number: 20190360060
    Abstract: The invention is a method of predicting response to therapy in a colorectal cancer patient, the method comprising analysis of circulating tumor DNA from a patient's sample.
    Type: Application
    Filed: August 7, 2019
    Publication date: November 28, 2019
    Inventors: John Lee, John Palma, Ulrich-Peter Rohr, Lijing Yao, Stephanie Yaung
  • COMPOSITIONS AND METHODS FOR PROGNOSING AND TREATING COLORECTAL CANCER
    Publication number: 20190269716
    Abstract: A combination of mismatch repair (MMR) and Metastasis Associated in Colon Cancer 1 (MACC1) gene expression status of the patient serve as a basis for risk stratification of early stage colon cancer patients. Patients with defective MMR (dMMR) status have improved survival and do not benefit from 5-fluorouracil (5-FU) therapies. In contrast, patients with a proficient MMR (pMMR) status have a higher risk of recurrence and worse survival. The pMMR patients are then further stratified on the basis of MACC1 gene expression. Patients with a pMMR status and a low MACC1 expression have a favorable prognosis similar to patients having a dMMR status, whereas patients having a pMMR status and high MACC1 expression have a less favorable prognosis.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Inventors: Pia Herrmann, Katharina Ilm, Katherine F. Leith, Andrea Muranyi, Ulrich-Peter Rohr, Kandavel Shanmugam, Shalini Singh, Ulrike Stein
  • G-Alpha Interacting Vesicle Associated Protein (GIV) as a Predictive Marker in Stage II Colorectal Cancer
    Publication number: 20170038385
    Abstract: Provided herein are methods of analyzing stage II colorectal cancer (CRC) samples (such as those that are mis-match repair proficient, pMMR), by scoring G-alpha interacting vesicle associated protein (GIV, also known as girdin) full-length (GIV-fl) expression in combination with lymphovascular invasion (LVI) status or clinical variables. The disclosed methods can be used to identify GIV-fl expressing tumors that are likely to recur (high risk) and those that are not likely to recur (high risk). Subjects identified as having a high risk CRC can be selected to receive chemotherapy or biotherapy for the CRC. Thus, in some examples, the disclosed methods can be used to identify CRC tumors that are likely to respond to chemotherapy or biotherapy. Also provided are computer implemented methods, systems, and kits that can be used with these methods.
    Type: Application
    Filed: August 16, 2016
    Publication date: February 9, 2017
    Inventors: Katherine Leith, Ulrich-Peter Rohr, Shalini Singh, Pradipta Ghosh, Song Hu, Bonnie LaFleur, Andrea Muranyi, Kandavel Shanmugam